Analysis of the Clinical Effects and Expression Levels of Inflammatory Cytokines in Type B AD Patients after TEVAR Therapy

Background/Aim: This study aims to investigate the clinical effects and expression levels of inflammatory cytokines in patients with type B acute aortic dissection (AD) after thoracic endovascular aortic repair (TEVAR) therapy. Methods: A retrospective analysis of 60 patients with acute AD admitted to our hospital from April 2016 to January 2018 was conducted. The patients were divided into control group (n=30) and TEVAR group (n=30) according to different treatment methods administered. The control group was given drug therapy (Urapidil+Felodipine+Diltiazem), and the TEVAR group was given with thoracic endovascular aortic repair therapy. The expression levels of inflammatory cytokines in both groups were measured before (pre) and after (post) the treatment. The therapeutic effects and the long-term outcomes of both groups were analyzed. Results: The post treatment result shows that the plasma levels of interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-α (TNF-α) were significantly decreased in both groups (P<0.01). Importantly, the plasma levels of IL-6, IL-8, and TNF-α in the TEVAR group were markedly lower than those in the control group (P<0.01). The number of white blood cells (WBC) and neutrophils decreased significantly in the two groups (P<0.05). The number of lymphocytes in the two groups also significantly increased (P<0.05). The numbers of WBC, neutrophils, and lymphocytes significantly differed between the TEVAR and control groups (P<0.05). The rate of efficacy in the TEVAR group was significantly higher than that in the control group (P<0.05). The 2-year survival rate in the TEVAR group was significantly higher than that in the control group (P<0.05). The postoperative complication rate in the TEVAR group was significantly lower than that in the control group (P<0.05). Conclusion: TEVAR exhibits good therapeutic effect by significantly inhibiting the expression of inflammatory cytokines and improving the survival rate to some extent.